RT Journal Article
SR Electronic
T1 Emergence and spread of a B.1.1.28-derived P.6 lineage with Q675H and Q677H Spike mutations in Uruguay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.27.21261150
DO 10.1101/2021.07.27.21261150
A1 Rego, Natalia
A1 Salazar, Cecilia
A1 Paz, Mercedes
A1 Costábile, Alicia
A1 Fajardo, Alvaro
A1 Ferrés, Ignacio
A1 Perbolianachis, Paula
A1 Fernández-Calero, Tamara
A1 Noya, Veronica
A1 Machado, Matias R.
A1 Arce, Rodrigo
A1 Arleo, Mailen
A1 Possi, Tania
A1 Reyes, Natalia
A1 Noel Bentancor, María
A1 Lizasoain, Andrés
A1 Bortagaray, Viviana
A1 Moller, Ana
A1 Chappos, Odhille
A1 Nin, Nicolas
A1 Hurtado, Javier
A1 Duquía, Melissa
A1 González, Belén
A1 Griffero, Luciana
A1 Méndez, Mauricio
A1 Pía Techera, Ma
A1 Zanetti, Juan
A1 Rivera, Bernardina
A1 Maidana, Matías
A1 Alonso, Martina
A1 Alonso, Cecilia
A1 Medina, Julio
A1 Albornoz, Henry
A1 Colina, Rodney
A1 Bello, Gonzalo
A1 Moreno, Pilar
A1 Moratorio, Gonzalo
A1 Iraola, Gregorio
A1 Spangenberg, Lucía
YR 2021
UL http://medrxiv.org/content/early/2021/07/31/2021.07.27.21261150.abstract
AB Uruguay was able to control the viral dissemination during the first nine months of the SARS-CoV-2 pandemic. Unfortunately, towards the end of 2020, the number of daily new cases exponentially increased. Herein we analyzed the country-wide genetic diversity of SARS-CoV-2 between November, 2020 and April, 2021. Our findings identified that the most prevalent viral variant during late 2020 was a B.1.1.28 sublineage carrying mutations Q675H+Q677H in the viral Spike, now designated as lineage P.6. This new lineage P.6 probably arose around November 2020, in Montevideo, Uruguay’s capital department and rapidly spread to other Uruguayan departments, with evidence of further local transmission clusters, also spread sporadically to the USA and Spain. The Q675H and Q677H mutations are in the proximity of the polybasic cleavage site at the S1/S2 boundary and also arose independently in many SARS-CoV-2 lineages circulating worldwide. Although the lineage P.6 was replaced by the Variant of Concern (VOC) P.1 as the predominant viral strain in Uruguay since April 2021, the monitoring of the concurrent emergence of Q675H+Q677H in VOCs should be of worldwide interest.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by FOCEM-Fondo para la Convergencia Estructural del Mercosur (COF03/11).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was done by the Inter-Institutional Working Group (IiWG) for SARS-CoV-2 genomic surveillance in Uruguay, which involves a diagnostic network, expertise and resources to handle large-scale sequencing, computational scientists for genomic analysis, and an affordable and decentralized in house qPCR test designed to detect known VOCs [6]. Residual de-identified RNA samples from SARS-CoV-2 positive patients were remitted to the Institut Pasteur de Montevideo (IPMon). IPMon was validated by the Ministry of Health of Uruguay as an approved center providing diagnostic testing for COVID-19. All samples were de-identified before receipt by the study investigators. All relevant ethical guidelines have been appropriately followed. Additionally, the project was approved by the Ethics Committee of the Sanatorio Americano SASA (Uruguay). Ethical approval was given and signed informed consent was obtained from the participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll SARS-CoV-2 genome sequences have been submitted to the EpiCoV/GISAID database with accession numbers indicated in Table S1.